Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BCAL DiagnosticsASX:BDX +1.54% Debt-to-Equity is 1.38 as of Dec. 2025, which is 500% above its 10-year median of 0.23. The stock has 3 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 87.43% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BCAL Diagnostics's Debt-to-Equity or its related term are showing as below:
ASX:BDX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.14 Med: 0.23 Max: 1.38
Current: 1.38
During the past 4 years, the highest Debt-to-Equity Ratio of BCAL Diagnostics was 1.38. The lowest was 0.14. And the median was 0.23.
ASX:BDX's Debt-to-Equity is ranked worse than 87.43% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.31
vs ASX:BDX: 1.38
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BCAL Diagnostics Debt-to-Equity Related Terms
BCAL Diagnostics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BDX vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, BCAL Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a Debt-to-Equity of 1.38 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BCAL Diagnostics and its competitors. This is 500% above median its historical median of 0.23. Over the past decade, BCAL Diagnostics' Debt-to-Equity has ranged from 0.14 to 1.38. According to the industry distribution chart, BCAL Diagnostics ranks #160 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 87.4%.
Is BCAL Diagnostics' Debt-to-Equity too high?
BCAL Diagnostics' current Debt-to-Equity of 1.38 is 500% above median its 10-year median of 0.23. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 1.38. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.31. BCAL Diagnostics' value of 1.38 is 345.2% above this industry median. Based on the distribution chart, BCAL Diagnostics ranks #160 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #160 out of 183 companies for Debt-to-Equity. This places BCAL Diagnostics in the lower half of its industry. The industry median Debt-to-Equity is 0.31. BCAL Diagnostics' value of 1.38 is 345.2% above this benchmark. Historically, BCAL Diagnostics' own Debt-to-Equity has ranged from 0.14 to 1.38 over the past decade. While the company's 10-year median is 0.23 vs. the industry median of 0.31, BCAL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BCAL Diagnostics's current Debt-to-Equity of 1.38 is 345.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current Debt-to-Equity is 1.38, which is 500% above median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Debt-to-Equity of 1.38. The current Debt-to-Equity is 1.38, which is 500% above median its 10-year median of 0.23 and 345.2% above the Medical Diagnostics & Research industry median of 0.31. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Debt-to-Equity is 1.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 
